Pfizer has signed a licensing agreement worth up to $6 billion with Chinese pharmaceutical products developer 3SBio Inc for the development, manufacturing and commercialization of a drug undergoing trials for treatment of certain types of cancer and tumours, the U.S. drugmaker said on Monday.

A quick look at the market, business, and economic news making headlines in China.

Pfizer announced it has entered into an exclusive global, ex-China, licensing agreement with 3SBio Inc., a leading Chinese biopharmaceutical company, for the development, manufacturing and commerciali...

Pfizer Inc. (NYSE: PFE) today announced it has entered into an exclusive global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK), a leading Chinese biopharmaceutical company, for the develop...

In the latest and largest deal between a China-based biotech and a larger biopharma for a bispecific with broad potential in oncology, Pfizer is paying 3SB...

3SBio (OTCMKTS:TRSBF – Get Free Report) is anticipated to post its results after the market closes on Thursday, August 20th. Analysts expect the company to post earnings of $0.0942 per share and revenue of $689.3230 million for the quarter. 3SBio Stock Performance Shares of OTCMKTS:TRSBF opened at $2.12 on Thursday. The firm’s 50 day moving [...]

Zinger Key Points - FDA advisors are planning to discuss if they should recommend COVID-19 vaccines for 2025-26 targeting the LP.8.1 subvariant. - Pfizer announces a licensing agreement with 3SBio to develop, manufacture and commercialize SSGJ-707 globally, excluding China. - Get 5 ‘Hidden Gem’…

Recombinant Human TNF Receptor–Fc Fusion Protein is a recombinant human TNF receptor II–Fc fusion protein, acting as a decoy for TNF, approved in China (NMPA No.S20233108; Code86981272000021). Designed to mimic etanercept but produced via CHO cells, it neutralizes , reducing inflammation in RA, psoriasis, and ankylosing spondylitis. Packaged as 25mg in 0.5mL prefilled syringe by 3SBio Pharma.

Recombinant Human TNF Receptor–Fc Fusion Protein is a recombinant human TNF receptor II–Fc fusion protein, acting as a decoy for TNF-α, approved in China (NMPA No. S20233108; Code 86981272000021). Designed to mimic etanercept but produced via CHO cells, it neutralizes TNF-α, reducing inflammation in RA, psoriasis, and ankylosing spondylitis. Packaged as 25 mg in 0.5 mL prefilled syringe by 3SBio Pharma. Strictly for laboratory/research use（Please consult the staff for other purposes）

Key takeaways Pfizer is een belangrijke samenwerking aangegaan met 3SBio, een toonaangevend Chinees biofarmaceutisch bedrijf. Deze exclusieve licentieovereenkomst verleent Pfizer wereldwijde rechten (met uitzondering van China) om SSGJ-707 te ontwikkelen, produceren en commercialiseren. SSGJ-707 is een bispecifiek antilichaam dat is ontworpen om PD-1 en VEGF te targeten. Het heeft veelbelovende initiële werkzaamheids- en veiligheidsgegevens laten […]

Pfizer and 3SBio have completed a licensing agreement that grants the US pharmaceutical giant worldwide rights to sell the Hong Kong-listed firm’s cancer drug, marking the largest deal ever for a single drug in China’s biotech industry. First announced in May, the deal will see 3SBio – based in Shenyang, capital of northeastern Liaoning province – receive a US$1.25 billion upfront payment from Pfizer for the exclusive right to sell its cancer drug, SSGJ-707, outside China. Under the terms of...

3Sbio Inc. reported interim phase II study results of its PD-1/VEGF bispecific antibody, SSGJ-707 – a “fabulous” asset, according to Pfizer Inc. CEO Albert Bourla, that landed in Pfizer’s cancer arsenal via a potential $6 billion deal in May, of which $1.2 billion was paid up front.